NasdaqGS:SDGRHealthcare Services
Schrödinger (SDGR) Is Up 6.5% After Refocusing On Core Software Platform Over Drug Development - What's Changed
Earlier this year, BofA Securities upgraded Schrödinger, Inc. after the company moved to prioritize its core software platform and scale back capital-intensive drug development, while KeyBanc reaffirmed a positive stance following discussions on product expansion and the software franchise.
The shift toward a simpler, software-centric model reduces clinical complexity and cash consumption, sharpening the investment focus on Schrödinger’s higher-margin, recurring-revenue business.
We’ll now...